Krishna Institute of Medical Sciences Limited (NSE:KIMS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Investors in Krishna Institute of Medical Sciences Limited (NSE:KIMS) had a good week, as its shares rose 4.1% to close at ₹642 following the release of its quarterly results. It was a pretty mixed result, with revenues beating expectations to hit ₹7.7b. Statutory earnings fell 4.1% short of analyst forecasts, reaching ₹2.22 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Krishna Institute of Medical Sciences after the latest results.

View our latest analysis for Krishna Institute of Medical Sciences

Taking into account the latest results, the consensus forecast from Krishna Institute of Medical Sciences' 13 analysts is for revenues of ₹38.7b in 2026. This reflects a major 35% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to surge 32% to ₹11.53. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹38.5b and earnings per share (EPS) of ₹11.62 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹638. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Krishna Institute of Medical Sciences, with the most bullish analyst valuing it at ₹750 and the most bearish at ₹404 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Krishna Institute of Medical Sciences' past performance and to peers in the same industry. The analysts are definitely expecting Krishna Institute of Medical Sciences' growth to accelerate, with the forecast 27% annualised growth to the end of 2026 ranking favourably alongside historical growth of 19% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 19% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Krishna Institute of Medical Sciences is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ₹638, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Krishna Institute of Medical Sciences going out to 2027, and you can see them free on our platform here..

You still need to take note of risks, for example - Krishna Institute of Medical Sciences has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.